Antibody-drug conjugates (ADCs) already sit close to the top of oncological treatments because, unlike many other therapies, they can selectively target and eradicate tumour cells. As the industry has refined this therapeutic approach, we’re now seeing ADCs being integrated with the capacity to modulate the immune system. This new addition to the ADC arsenal marks a progressive shift, bolstering the fight against cancer with a focus on increasing immunotherapy potency.
Pharmaceutical Manufacturer’s latest issue feature’s Abzena’s CSO, Dr @CampbellBunce in “When ADCs Team Up with Immune Modulators to Fight Cancer.”
Check out the article here: Link
